Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Regen BioPharma (RGBP) EPS (Basic) (2016 - 2025)

Regen BioPharma (RGBP) has disclosed EPS (Basic) for 13 consecutive years, with -$0.01 as the latest value for Q2 2025.

  • On a quarterly basis, EPS (Basic) rose 66.67% to -$0.01 in Q2 2025 year-over-year; TTM through Jun 2025 was -$0.17, a 71.72% decrease, with the full-year FY2024 number at -$0.16, down 156.18% from a year prior.
  • EPS (Basic) was -$0.01 for Q2 2025 at Regen BioPharma, down from -$0.0 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $19.06 in Q2 2022 to a low of -$22.19 in Q1 2022.
  • A 5-year average of -$0.07 and a median of -$0.02 in 2025 define the central range for EPS (Basic).
  • Biggest YoY gain for EPS (Basic) was 907935.84% in 2022; the steepest drop was 2579761.63% in 2022.
  • Regen BioPharma's EPS (Basic) stood at $0.0 in 2021, then soared by 43001.38% to $0.43 in 2022, then tumbled by 109.28% to -$0.04 in 2023, then tumbled by 225.0% to -$0.13 in 2024, then soared by 92.31% to -$0.01 in 2025.
  • Per Business Quant, the three most recent readings for RGBP's EPS (Basic) are -$0.01 (Q2 2025), -$0.0 (Q1 2025), and -$0.13 (Q4 2024).